| Document |
Document Title |
|
WO/2024/044141A1 |
Provided herein are methods for treating overactive bladder (OAB) and stress urinary incontinence (SUI). The method for treating OAB includes administering a therapeutically effective amount of plasma adjacent to a subject's posterior bl...
|
|
WO/2024/041460A1 |
The present invention provides compounds of Formula (I) : wherein all of the variables are as defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for the...
|
|
WO/2024/044547A1 |
Described herein are antibodies and immunoconjugates capable of targeting antigens within the kidney. The antibodies described herein generally a polypeptide, wherein the polypeptide comprises: an antigen-binding domain (e.g., immunoglob...
|
|
WO/2024/041236A1 |
A fusion protein ANGPTL3 monoclonal antibody-B comprising an ANGPTL3 monoclonal antibody is formed by fusing the ANGPTL3 monoclonal antibody with a sequence B. The fusion protein ANGPTL3 monoclonal antibody-B is used for treating disease...
|
|
WO/2024/042316A1 |
This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and discoidin doma...
|
|
WO/2023/246870A9 |
Disclosed in the present invention are a preparation, application and use of an indole compound, and particularly disclosed are a compound as shown in a formula (I), an optical isomer or pharmaceutically acceptable salt thereof, and usin...
|
|
WO/2024/041633A1 |
Disclosed is use of a fused ring pyrimidine compound or a pharmaceutically acceptable salt thereof. The structure of the fused ring pyrimidine compound is represented by formula I. The fused ring pyrimidine compound can be used for prepa...
|
|
WO/2024/043232A1 |
The purpose of the present invention is to provide a novel therapeutic agent for renal disease. The present invention is a therapeutic agent for renal disease containing a mesenchymal stem cell culture supernatant. The mesenchymal stem...
|
|
WO/2024/038128A1 |
The present invention relates to compounds of Formulas I to V and la to Va, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment...
|
|
WO/2024/038132A1 |
The present invention relates to compounds of Formulas I to IV, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or preventi...
|
|
WO/2024/039268A1 |
The present invention relates to the field of medicine, and more particularly to a method for treating a disease or disorder mediated by T-lymphocytes bearing a TRBV9 segment within the T-cell receptor, which includes administering an an...
|
|
WO/2024/037644A1 |
The present invention provides a polyethylene glycol (PEG)-modified glucocorticoid medicament and use thereof, including, but not limited to, asthma, chronic obstructive pulmonary disease, bronchitis, rhinitis, and the like, and relates ...
|
|
WO/2024/038129A1 |
The present invention relates to compounds of Formulas I to V and Ib to Vb, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment...
|
|
WO/2024/039593A1 |
This invention relates to a ready to use, orally administered formulation containing a therapeutically effective amount of calcium as calcium succinate monohydrate with unexpected palatability, chemical and physical stability, and availa...
|
|
WO/2024/032713A1 |
Provided are compositions comprising the HKUOT-S2 protein, at least one peptide according to at least one of SEQ ID NO: 81-97, or proteins comprising an amino acid sequence according to at least one of SEQ ID NO: 81-97. Provided are meth...
|
|
WO/2023/038927A9 |
Provided herein are methods for treatment of bladder cancer, such as non-muscle invasive bladder cancer, by targeted injection of a therapeutic agent to the lamina propria of the bladder wall that comprises or is proximate to a bladder c...
|
|
WO/2024/034495A1 |
This urinary tract infection prevention/treatment agent is characterized in containing 1-deoxymannose.
|
|
WO/2024/032589A1 |
Provided are a TGF-β inhibitor compound and use thereof. In particular, provided is a compound represented by formula (I) or formula (II) or an isotopically labeled compound, an optical isomer, a geometric isomer, a tautomer, an isomer ...
|
|
WO/2024/033705A1 |
Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions...
|
|
WO/2024/034322A1 |
[Problem] The purpose of the present invention is to provide an enhancing agent having a useful action such as an enhancement action on a cardiolipin molecular species that is a mitochondrial inner membrane component having 3,5-dihydroxy...
|
|
WO/2024/031997A1 |
The present invention relates to N-N-bis-oxazolidinone alkaloid compounds, a preparation method and a use in the medical field. The present invention provides two new N-N-bis-oxazolidinone alkaloid isomers isolated and purified from Loni...
|
|
WO/2024/028764A1 |
The present invention relates to the Lacticaseibacillus rhamnosus DSM 33960 bacterial strain, and its use in a method for the prevention and treatment of conditions of dysbiosis of the female urogenital tract, preferably vaginal dysbiosis
|
|
WO/2024/028599A1 |
The present invention belongs to the field of chemical pharmaceuticals and relates to novel forms of Methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate. Specifically, the invention relates to the 2-ketoglutarate and p-toluenesulphonate s...
|
|
WO/2024/027752A1 |
Provided are a pharmaceutical composition comprising a heterocyclic compound, a preparation method therefor, and use thereof. Further provided is a pharmaceutical composition Q, comprising a substance X and a pharmaceutical excipient, th...
|
|
WO/2024/029593A1 |
The present disclosure includes: a polynucleotide comprising a sequence encoding shortened polycystin-1 (PC1) having a cyst formation-inhibiting activity, in which the shortened PC1 contains a PC1 C-terminal tail (CTT) domain or a part t...
|
|
WO/2024/029560A1 |
Provided is a therapeutic agent for Hunner-type interstitial cystitis that can selectively inhibit IFN-γ, does not have a risk of biological contamination, and can be stored at room temperature. Provided is a therapeutic agent for Hunne...
|
|
WO/2024/029599A1 |
Provided is a pharmaceutical composition containing, as an active ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methox
yphenyl)pyrrolidine-3-yl]carbonyl}-4-(methoxymethyl)pyrrolid
ine-3-yl]-5-(trifluoromethyl)phenyl}p...
|
|
WO/2024/024985A1 |
Provided is a drug for treating Alzheimer's disease, the drug enabling retention of cognitive function amelioration and nerve quality improvement for a specific time even after treatment ends. This drug for causal treatment of Alzheime...
|
|
WO/2024/024565A1 |
The present invention addresses the problem of providing an agent that suppresses cell aging and a drug that prevents or treats diseases and the like caused by cell aging. More specifically, the present invention is a cell aging suppress...
|
|
WO/2024/026354A2 |
Provided herein are compositions and methods of use thereof for treating Autosomal recessive polycystic kidney disease (ARPKD) by targeting RAC1 and/or FOS.
|
|
WO/2024/026399A1 |
Prebiotic formulations can modulate the growth and/or activity of microorganisms in the urogenital area. Such prebiotic formulations can comprise isomaltulose along with at least one other prebiotic, such as 1-kestose or lactulose. These...
|
|
WO/2024/023785A1 |
The present disclosure provides oral suspension formulations of drotaverine or a salt thereof, methods of their preparation, and their use in treatment.
|
|
WO/2024/022481A1 |
The present invention belongs to the technical field of medicines. Disclosed are phenyl-substituted dihydronaphthyridine compounds and preparation and use thereof. The compound disclosed by the present invention is represented by formula...
|
|
WO/2024/023786A1 |
The present disclosure provides palatable orally disintegrating tablet formulations of drotaverine or a salt thereof, methods of their preparation, and their use in treatment.
|
|
WO/2024/023745A1 |
The present invention pertains to the use for treating organ injury, in particular acute organ injury, such as acute kidney injury (AKI) using CD39, human recombinant CD39 and variants thereof.
|
|
WO/2024/019596A1 |
The present invention relates to a sustained-release formulation containing a 5-alpha-reductase inhibitor, and can be used for the prevention, amelioration, or treatment of prostatic hyperplasia and alopecia.
|
|
WO/2024/017331A1 |
The present invention belongs to the fields of bioengineering and biological treatment. Disclosed are an anti-ADM monoclonal antibody or a fragment thereof and a pharmaceutical composition, a detection reagent, or a kit comprising the mo...
|
|
WO/2024/017310A1 |
The present invention relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating and/or preventing renal fibrosis and/or renal diseases related to...
|
|
WO/2024/018245A1 |
Diabetic kidney disease is associated with impaired podocyte autophagy and subsequent podocyte injury. In the present invention, the inventors investigated how the calcium channel TRPC6 and the cysteine protease calpains impair podocyte ...
|
|
WO/2024/017144A1 |
Provied are a class of substituted imidazo[1,2-a]pyridine compounds, pharmaceutical compositions containing the same, and use of the compounds in the treatment and prevention of fibrosis.
|
|
WO/2024/020458A1 |
The present invention relates to the use of Apoptosis Signal-Regulating Kinase- 1 (ASK-1) inhibitor compounds for the treatment of organ diseases and disorders, wherein the organ disease or disorder is selected from a liver, heart diseas...
|
|
WO/2024/017915A1 |
The present technology relates to a polypeptide comprising at least three immunoglobulin single variable domains (ISVDs). In particular, the present technology relates to a polypeptide comprising an optimized ISVD binding to fractalkine ...
|
|
WO/2024/017366A1 |
Provided are a compound of formula (I) having an effect of regulating and controlling the activity of 15-PGDH, a stereoisomer, a tautomer or a form of a mixture thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof...
|
|
WO/2024/020105A1 |
Provided herein are drug implants comprising Darolutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and Darolutamide disposed therein. Additionally provided are methods for m...
|
|
WO/2024/014463A1 |
The present invention provides a drug for suppressing the growth of kidney stones, the drug containing a peptide that includes an amino acid sequence satisfying the following conditions or a nucleic acid that encodes said peptide: (1) Am...
|
|
WO/2024/014941A1 |
The present invention relates to a composition for treating, alleviating or preventing kidney diseases and, more particularly, to a pharmaceutical or food composition for treating, alleviating or preventing kidney diseases, containing, a...
|
|
WO/2024/008114A1 |
The present invention relates to an siRNA capable of inhibiting the expression of a complement factor B (CFB) gene, an siRNA conjugate, a pharmaceutical composition comprising same, and a use thereof. Each nucleotide in the siRNA is inde...
|
|
WO/2024/010015A1 |
Compounds represented by general formula (1), the compounds having strong inhibitory action against mPGES-1 and being useful as active ingredients for pharmaceuticals for the treatment of inflammation and the like.
|
|
WO/2024/011220A1 |
The present invention provides compositions and methods of preventing, alleviating, or treating a subject with a toxic agent-induced injury. The present invention also provides compositions and methods of preventing, alleviating, or trea...
|
|
WO/2024/011138A1 |
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropio...
|
